Keyword: high-cost drugs

43 results found

As the coronavirus pandemic enters its fourth year, it’s perhaps unsurprising that the health crisis has taken its toll on employee mental health. Scotiabank saw a notable rise in claims for mental-health drugs in 2022, says Ayman Alvi, the bank’s vice-president of global pension and benefits, noting the increased use of these medications aligns with […]

Changes to Ontario’s policy on the use of biosimilars in its public drug plan could result in savings for private benefits plans if they choose to follow the provincial model, says Theresa Tran, a principal in group benefits at Eckler Ltd. Starting March 31, Ontario Drug Benefit recipients who are on an originator biologic will […]

  • By: Blake Wolfe
  • February 16, 2023 February 15, 2023
  • 09:00

Running for more than 17 years, Benefits Canada‘s Face to Face Drug Plan Management Forum is the industry’s most popular drug benefits conference. In 2022, the event returned to a face-to-face format at the Sheraton Centre in Toronto on Dec. 6. Attendees learned about fresh drug plan design insights, including a new drug launch panel […]

Plan sponsors face challenges balancing benefits plan sustainability while also ensuring their plan members have access to the care they need, said Marie-Hélène Dugal, manager of pharmacy benefit strategy at Medavie Blue Cross, during a session at Benefits Canada’s 2022 Face to Face Drug Plan Management Forum in Toronto in December. Referring to Medavie’s claims data, […]

With the cost of drug claims continuing to rise in 2021, benefits plan sponsors can enable certain drug programs to curb costs, keeping their plans sustainable and offering the benefits that members highly value, said Lavina Viegas, director of pharmacy operations at Telus Health, during a session at Benefits Canada’s 2022 Face to Face Drug […]

About a million Canadians are impacted by rare diseases, which disproportionately affect younger patients — 70 per cent start in childhood and, sadly, half of these children won’t reach adulthood, said Suzanne Lepage, a private health plan strategist, during a session supported by Alexion Pharmaceuticals at Benefits Canada‘s 2022 Face to Face Drug Plan Management Forum […]

An article on the potential impacts of a pension super-priority bill was the most-read story on BenefitsCanada.com over the last week. Here are the five most popular news stories of the week: 1. Pension super-priority bill passes in House of Commons 2. Ontario municipality establishing six-week indoor mask requirement for city employees 3. CIBC supporting employee health with wellness […]

  • By: Staff
  • December 2, 2022 December 1, 2022
  • 09:00

The increasing use of high-cost medicines is the primary cost driver for all Canadian drug plans, according to a new report by the Patented Medicine Prices Review Board. It found drug costs for public plans rose by 5.3 per cent in 2019/20, with high-cost medicines accounting for 6.3 per cent of the increase. Among private […]

  • By: Staff
  • November 25, 2022 November 24, 2022
  • 09:00

Amid the increasing introduction of specialized medicines in Canada, key stakeholders in the private payer health-care sector are enhancing their collaborations to maintain the value of private drug coverage, said Joe Farago, executive director of private payers and investment at Innovative Medicines Canada, during a webinar by the Group Insurance Pharmaceutical Committee this week. “[The […]

Copyright_Aleksandr Kalugin_123RF

Imagine that a few pills a day could transform an employee’s life — that they could get back to work, perform better, have fewer sick days, be more present and avoid continuously deteriorating health. Now, what if this life-changing medicine is for a rare disease that isn’t covered under the employee’s benefits plan because of […]